1fvb: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
==MODEL-BUILDING STUDY OF THE COMBINING SITES OF TWO ANTIBODIES TO ALPHA(1(RIGHT ARROW)6)DEXTRAN== | ==MODEL-BUILDING STUDY OF THE COMBINING SITES OF TWO ANTIBODIES TO ALPHA(1(RIGHT ARROW)6)DEXTRAN== | ||
<StructureSection load='1fvb' size='340' side='right' caption='[[1fvb]]' scene=''> | <StructureSection load='1fvb' size='340' side='right'caption='[[1fvb]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1FVB FirstGlance]. <br> | <table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1FVB FirstGlance]. <br> | ||
| Line 21: | Line 21: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Theoretical Model]] | [[Category: Theoretical Model]] | ||
[[Category: Large Structures]] | |||
[[Category: Kabat, E A]] | [[Category: Kabat, E A]] | ||
[[Category: Padlan, E A]] | [[Category: Padlan, E A]] | ||
Revision as of 11:52, 23 October 2019
 |
MODEL-BUILDING STUDY OF THE COMBINING SITES OF TWO ANTIBODIES TO ALPHA(1(RIGHT ARROW)6)DEXTRANMODEL-BUILDING STUDY OF THE COMBINING SITES OF TWO ANTIBODIES TO ALPHA(1(RIGHT ARROW)6)DEXTRAN
Structural highlights
Publication Abstract from PubMedModels of the Fv portion (containing the variable regions of the heavy and light chains) of two monoclonal anti-alpha (1----6)dextran antibodies, W3129 and 19.1.2, were constructed from amino acid sequences and the known three-dimensional structures of the Fv portions of McPC603 and J539. The modeled combining site of W3129 has a protrusion on one side, formed by the long complementarity-determining region 1 of the light chain and the long complementarity-determining region 3 of the heavy chain, and has a cavity accommodating a glucose moiety. The model of the 19.1.2 site is basically flat with a shallow groove that can accommodate several internal glucose units. These results support the earlier conclusions, from ligand binding data, that W3129 has a cavity-type site, involving the terminal nonreducing glucose residue (endbinder), whereas 19.1.2 has a groove-type site. Model-building study of the combining sites of two antibodies to alpha (1----6)dextran.,Padlan EA, Kabat EA Proc Natl Acad Sci U S A. 1988 Sep;85(18):6885-9. PMID:2457920[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References |
| ||||||||||||||